Vicarious Surgical Reports Q3 2025 Financial Results with Reduced Losses and Ongoing Development of Surgical Robot

Vicarious Surgical Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $11.1 million, or $1.86 per share, compared to a net loss of $17.1 million, or $2.90 per share, for the same period in 2024. For the nine months ended September 30, 2025, the company incurred a net loss of $39.7 million, a decrease from the $49.3 million loss reported in the prior year. The reduction in losses is attributed to a 35% decrease in total operating expenses, which fell to $11.5 million for the quarter, driven primarily by lower research and development costs and reduced general and administrative expenses.

The company’s total operating expenses for the nine months ended September 30, 2025, were $40.8 million, down from $51.6 million in the same period of 2024. Research and development expenses decreased by 17% to $26.5 million, while sales and marketing expenses dropped by 51% to $1.7 million. General and administrative expenses also saw a reduction of 23%, totaling $12.6 million. The decrease in personnel-related expenses, including a reduction in average headcount, contributed significantly to the overall decline in operating costs.

Vicarious Surgical remains focused on the development of its single-port surgical robot, which aims to enhance minimally invasive surgical procedures. The company has not yet generated revenue, as it awaits FDA authorization for its Vicarious Surgical System. The company has engaged in discussions with the FDA regarding its regulatory strategy and plans to file a de novo application for ventral hernia procedures. The company anticipates a clinical-ready version of its system by mid-2026, with first-in-human clinical trials expected to begin in 2027.

As of September 30, 2025, Vicarious Surgical reported cash and cash equivalents of $3.2 million and short-term investments of $10.3 million, down from $51.7 million at the end of 2024. The company has expressed concerns about its ability to continue as a going concern, indicating that its current cash reserves, along with net proceeds from a recent direct offering, may not be sufficient to support operations beyond the first quarter of 2026. To address its capital needs, Vicarious Surgical is actively pursuing additional financing options.

In recent strategic developments, the company completed a registered direct offering in October 2025, raising approximately $5.2 million. Additionally, Vicarious Surgical amended its office lease to reduce its space, which is expected to help manage costs. The company continues to work on improving its internal controls and has acknowledged material weaknesses in its financial reporting processes, which it is actively addressing.